Geneva, Switzerland, January 9, 2018 – 6:00 pm CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases, such as multiple sclerosis (MS) and type 1 diabetes (T1D), announced today that patient enrollment in its Australian Phase 2a study of GNbAC1 in T1D has been completed on schedule. A total of 60 adult patients in more than 10 centers have been recruited into the study.

For more information :